As heterobivalent peptides gain prominence in targeted radionuclide therapy, the 177Lu-iPSMA-RGD peptide, which targets both PSMA and αvβ3 integrins, serves as a key example, designed to enhance tumor targeting and improve therapeutic results. Here, FOLH1 is linked to neoplasm.